PERSEUS 6-Year Results: D-VRd Improves Myeloma PFS & Supports Dual Maintenance | IMS 2026

Pieter Sonneveld, MD, PhD, of Erasmus MC discusses six-year follow-up from the PERSEUS trial at IMS 2026 in Glasgow. The trial added subcutaneous daratumumab to VRd, transplant and maintenance for newly diagnosed myeloma. He explains how the progression-free survival advantage of D-VRd has kept widening, especially in standard-risk patients, and how daratumumab plus lenalidomide maintenance deepened responses, allowing many MRD-negative patients to stop daratumumab after two years. He encourages patients to ask their doctors about dual maintenance.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.